Loading clinical trials...
Loading clinical trials...
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
Conditions
Interventions
SB-318
Locations
1
United States
UCSF Benioff Children's Hospital Oakland
Oakland, California, United States
Start Date
May 24, 2017
Primary Completion Date
November 3, 2021
Completion Date
November 3, 2021
Last Updated
January 26, 2023
NCT04088734
NCT01372228
NCT03632213
NCT04284254
NCT03811028
NCT02293408
Lead Sponsor
Sangamo Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions